Share on StockTwits

Eleven Biotherapeutics (NASDAQ:EBIO) major shareholder Jafco Super V3 Investment Limi sold 2,000 shares of the company’s stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $11.75, for a total transaction of $23,500.00. Following the transaction, the insider now directly owns 2,125,291 shares in the company, valued at approximately $24,972,169. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Shares of Eleven Biotherapeutics (NASDAQ:EBIO) traded up 0.59% on Friday, hitting $11.91. The stock had a trading volume of 40,581 shares. Eleven Biotherapeutics has a one year low of $9.502 and a one year high of $19.333. The stock’s 50-day moving average is $12.08 and its 200-day moving average is $13.01. The company’s market cap is $183.3 million.

Eleven Biotherapeutics (NASDAQ:EBIO) last announced its earnings results on Wednesday, August 13th. The company reported ($0.51) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.47) by $0.04. Analysts expect that Eleven Biotherapeutics will post $-1.84 EPS for the current fiscal year.

Eleven Biotherapeutics, Inc, is a United States-based company, which develops protein-based biotherapeutics.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.